754
Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.
 men with metastatic castration-resistant prostate cancer (mCRPC): Subject; men: Subject.Gender; Abiraterone acetate, an androgen biosynthesis inhibitor: Treatment; Abiraterone acetate: Treatment.Drug; metastatic castration-resistant prostate cancer: Treatment.Disorder
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 men with metastatic castration-resistant prostate cancer (mCRPC): Subject; men: Subject.Gender; Abiraterone acetate, an androgen biosynthesis inhibitor: Treatment; Abiraterone acetate: Treatment.Drug; metastatic castration-resistant prostate cancer: Treatment.Disorder